Dinatale Rg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6160378/publications.pdf

Version: 2024-02-01

840585 552653 30 854 11 26 citations h-index g-index papers 32 32 32 1134 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	13.5	223
2	Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. European Urology Focus, 2022, 8, 1278-1288.	1.6	11
3	Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome. Modern Pathology, 2022, 35, 825-835.	2.9	14
4	Urethral Melanoma – Clinical, Pathological and Molecular Characteristics. Bladder Cancer, 2022, 8, 291-301.	0.2	1
5	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 2022, 12, 2308-2329.	7.7	7
6	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. European Urology, 2021, 79, 468-477.	0.9	35
7	Identifying Clear Cell Renal Cell Carcinoma Coexpression Networks Associated with Opioid Signaling and Survival. Cancer Research, 2021, 81, 1101-1110.	0.4	10
8	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. European Urology Focus, 2021, 7, 381-389.	1.6	28
9	A qualitative framework of non-selection factors for cytoreductive nephrectomy. World Journal of Urology, 2021, 39, 3359-3365.	1.2	3
10	Single-cell sequencing links multiregional immune landscapes and tissue-resident TÂcells in ccRCC to tumor topology and therapy efficacy. Cancer Cell, 2021, 39, 662-677.e6.	7.7	179
11	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 5595-5606.	3.2	12
12	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer, 2021, 127, 3946-3956.	2.0	12
13	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma – An exploratory analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 791.e17-791.e24.	0.8	3
14	Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 755-762.	0.8	9
15	The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. Urology, 2020, 136, 169-175.	0.5	9
16	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. European Urology Oncology, 2020, 3, 47-56.	2.6	20
17	Preoperative nomogram predicting 12-year probability of metastatic renal cancer – evaluation in a contemporary cohort. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 853.e1-853.e7.	0.8	6
18	Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. British Journal of Anaesthesia, 2020, 125, e402-e404.	1.5	15

#	Article	IF	CITATIONS
19	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nature Communications, 2020, 11, 4168.	5.8	46
20	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy., 2020, 8, e000230.		37
21	An evaluation of the role of tumor load in cytoreductive nephrectomy. Canadian Urological Association Journal, 2020, 14, E625-E630.	0.3	1
22	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Scientific Reports, 2020, 10, 701.	1.6	21
23	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. Clinical Cancer Research, 2020, 26, 3629-3640.	3.2	30
24	Editorial Comment. Journal of Urology, 2020, 204, 101-102.	0.2	0
25	Altering the Natural History of Surgical Relapse in Testicular Cancer: Suboptimal Surgery and Pneumoperitoneum. European Urology, 2019, 76, 612-614.	0.9	7
26	The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 916-923.	0.8	8
27	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 811.e9-811.e16.	0.8	6
28	Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. Clinical Genitourinary Cancer, 2019, 17, e678-e688.	0.9	41
29	Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. Journal of Urology, 2018, 200, 275-282.	0.2	31
30	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. European Urology Focus, 2018, 4, 986-994.	1.6	29